SEC filing record
Primary Source · SEC.gov

Climb Bio, Inc.

2026 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-05-045 events: 3 new form d filer, 2 large raiseLast filing 2026-05-04

Raised

$110M

Investors

22

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Climb Bio, Inc. is a Delaware corporation that first filed a Form D on February 19, 2019 and most recently amended it on May 4, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Climb Bio, Inc. reported $110,076,289 sold from 22 investors of a $110,076,289 total offering as of the Form D filed May 4, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Leerink Partners LLC (CRD 39011), associated with None; Piper Sandler and Co. (CRD 665), associated with None; Raymond James & Associates, Inc. (CRD 705), associated with None; BTIG, LLC (CRD 122225), associated with None and 2 others as recipients of sales compensation soliciting in all states. Sales commissions are reported as $6,304,577 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 20 William Street, Suite G50, Wellesley Hills, MA.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001768446
Entity NameClimb Bio, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address20 William Street, Suite G50, Wellesley Hills, MA
Phone1-866-857-2596
Former NamesEliem Therapeutics, Inc. (until September 20, 2024)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateApril 29, 2026
Filing DateMay 4, 2026
Accession Number0001768446-26-000001
Total Offering Amount$110,076,289
Total Amount Sold$110,076,289
Amount Remaining$0
Total Investors22
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$6,304,577 (to Leerink Partners LLC and 5 others)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MA
Amendment Count8 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

5

latest May 4, 2026

Critical / warning

0 / 0

5 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

7

closed, lapsed

Latest event New filer · May 4, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 5 filing events with values and deltas, latest 2026-05-04, and alerts on the next one
  • 7 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-05-04: 5 related persons added and 4 removed against the filing of 2024-07-02; 9 now listed. The names are in the Terminal feed.

Aoife Brennan

Executive Officer, Director · Wellesley Hills, MA

Susan Altschuller

Executive Officer · Wellesley Hills, MA

Perrin Wilson

Executive Officer · Wellesley Hills, MA

Judith Dunn

Director · Wellesley Hills, MA

Stephen Thomas

Director · Wellesley Hills, MA

Douglas Williams

Director · Wellesley Hills, MA

Alexander (Bo) Combo

Director · Wellesley Hills, MA

Andrew Levin

Director · Wellesley Hills, MA

Kimberlee Drapkin

Director · Wellesley Hills, MA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in all states

Piper Sandler and Co.CRD 665 on BrokerCheck

Associated broker-dealer: None · Minneapolis, MN · Soliciting in all states

Raymond James & Associates, Inc.CRD 705 on BrokerCheck

Associated broker-dealer: None · St. Petersburg, FL · Soliciting in all states

BTIG, LLCCRD 122225 on BrokerCheck

Associated broker-dealer: None · San Francisco, CA · Soliciting in all states

Robert W. Baird & Co. IncorporatedCRD 8158 on BrokerCheck

Associated broker-dealer: None · Milwaukee, WI · Soliciting in all states

H.C. Wainwright & Co., LLCCRD 375 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Questions About Climb Bio, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Climb Bio, Inc.?

Climb Bio, Inc. is a Delaware corporation that filed a Form D with the SEC on May 4, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Climb Bio, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Climb Bio, Inc. filed a Form D with the SEC on May 4, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $110,076,289 sold to 22 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Climb Bio, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Climb Bio, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Climb Bio, Inc. raised?

Climb Bio, Inc. reported $110,076,289 sold from 22 investors of a $110,076,289 total offering as of the Form D filed May 4, 2026.

Who can invest in Climb Bio, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Climb Bio, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Climb Bio, Inc. and how are they paid?

The Form D names Leerink Partners LLC (CRD 39011), associated with None; Piper Sandler and Co. (CRD 665), associated with None; Raymond James & Associates, Inc. (CRD 705), associated with None; BTIG, LLC (CRD 122225), associated with None and 2 others as recipients of sales compensation soliciting in all states. Sales commissions are reported as $6,304,577 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Climb Bio, Inc.?

The Form D lists 9 related persons: Aoife Brennan, executive officer, director; Susan Altschuller, executive officer; Perrin Wilson, executive officer; Judith Dunn, director; Stephen Thomas, director; Douglas Williams, director; Alexander (Bo) Combo, director; Andrew Levin, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Climb Bio, Inc. located?

The issuer's address on its SEC filings is 20 William Street, Suite G50, Wellesley Hills, MA. Its phone number of record is 1-866-857-2596. It is organized under the laws of Delaware.

How long is the Climb Bio, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Climb Bio, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.